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Abstract: Fabry disease is caused by mutations in the GLA gene and is characterized by a large
genotypic and phenotypic spectrum. Missense mutations pose a special problem for graduating
diagnosis and choosing a cost-effective therapy. Some mutants retain enzymatic activity, but are
less stable than the wild type protein. These mutants can be stabilized by small molecules
which are defined as pharmacological chaperones. The first chaperone to reach clinical trial is
1-deoxygalactonojirimycin, but others have been tested in vitro. Residual activity of GLA mutants
has been measured in the presence or absence of pharmacological chaperones by several authors.
Data obtained from transfected cells correlate with those obtained in cells derived from patients,
regardless of whether 1-deoxygalactonojirimycin was present or not. The extent to which missense
mutations respond to 1-deoxygalactonojirimycin is variable and a reference table of the results
obtained by independent groups that is provided with this paper can facilitate the choice of eligible
patients. A review of other pharmacological chaperones is provided as well. Frequent mutations
can have residual activity as low as one-fourth of normal enzyme in vitro. The reference table with
residual activity of the mutants facilitates the identification of non-pathological variants.
Keywords: Fabry disease/drug therapy; α-galactosidase; pharmacological chaperones;
1-deoxynojirimycin
1. Introduction
Fabry disease (FD, OMIM #301500) is a rare pathology, but accounts for 8.8% of the patients
affected by inherited disorders of metabolism [1] and is the second most common lysosomal storage
disorder [2]. FD is caused by those mutations in the GLA gene that result in a deficiency of the protein
product, lysosomal α-galactosidase (AGAL Uniprot: AGAL_HUMAN P06280; EC: 3.2.1.22), and the
accumulation of its substrates. The real incidence of FD is difficult to establish. It was estimated at
1 in 100,000 [3].
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Screening of various at-risk populations, patients with renal failure [4,5], stroke [6],
and cardiomyopathy [7,8], have shown a significant prevalence of FD in symptomatic population.
GLA gene variations have been found in newborn screening with a frequency as high as 1 in 1200 or
1 in 3100 [9,10]. Some of the found variations remain unclear with respect to clinical significance.
Although GLA is located on X chromosome (Xq22.1), heterozygous females can be symptomatic.
This is due to random inactivation and lack of cross-correction that occurs in other lysosomal
storage disorders such as mucopolysaccharidosis type II [11]. Random X-chromosome inactivation in
heterozygous females leads to a mosaic of cells, half of which express wild-type AGAL. Under these
circumstances, female patients have mild or no signs of the disease. In some cases, however, a skewed
inactivation, which occurs for unknown reasons, leads to the preferential expression either of the
chromosome carrying the wild type or the mutant GLA. Under these circumstances, female patients
can be as severely affected as much as the male patients carrying the same mutation [12].
AGAL is a homodimeric glycoprotein with 429 amino acids per chain and shares structural
similarities with the other lysosomal glycosidases. It catalyzes the removal of α-galactosyl residues
from glycosphingolipids, in particular globotriaosylceramide, Gb3 or GL-3 (also known as ceramide
trihexoside). Its products are lactosylceramide and galactose. Gb3 mainly occurs in the endothelial,
kidney, heart, and nervous cells and there is evidence suggesting its involvement in the renal
pathology [13,14], but the underlying mechanism remains largely unknown [15]. Gb3 and its
isoforms based on ceramide modification are detectable in blood and urinary samples [16,17] from
the patients for the use as diagnostic and prognostic biomarkers following and supporting genetic
testing. Meanwhile, a deacylated metabolite of Gb3, globotriaosylsphingosine (lyso-Gb3) has emerged
as a superior biomarker demonstrating higher sensitivity than Gb3 and a good correlation to the FD
phenotype [18].
FD is characterized by a large phenotypic spectrum, with mildly and severely affected patients,
and shares many symptoms with common diseases. In severe cases, often referred to as classic FD,
the first specific signs appearing in childhood or adolescence are angiokeratoma, cornea verticillata,
neuropathic pain, acroparesthesias and hypohidrosis. These are followed by progressive proteinuric
renal insufficiency, rhythm and conductance disorders with progressive hypertrophic cardiomyopathy
and cerebrovascular stroke [19–21]. In mild cases, often referred to as atypical FD, only some symptoms
are present, usually the cardiac ones. The Mainz Severity Score Index (MSSI) [22,23] was developed to
measure the severity of FD and to monitor the clinical course of the disease in response to therapy.
The MSSI includes four components or sub-scores that assess the general, neurological, cardiovascular
and renal signs and symptoms. Although the MSSI score is able to differentiate FD from other
severe debilitating diseases, a minor, still significant overlap, in particular for cardiac sub-scores,
between healthy and FD affected persons was observed. MSSI was originally developed for classic FD.
Other tools, such as Fabry Disease Severity Scoring System (DS3) [24] and Fabry STabilization indEX
(FASTEX) [25], were subsequently developed to cover a broader range of cases.
The broad heterogeneous symptom spectrum might be due in part to genetic modifiers and other
extra-genetic (epigenetic, environmental) factors that are currently discussed [26,27].
Enzyme replacement therapy (ERT) has been approved for the last 15 years. There exist
two formulations of the recombinant AGAL, agalsidase α or β, that are commercialized by Shire,
Lexington, MA, USA and Genzyme, a Sanofi company, Cambridge, MA, USA respectively [28].
ERT may decrease cardiac mass [29–32] and reduce the accumulation of the substrate Gb3
in the kidney [33–35], but the effects on nervous system and renal function have not been
definitively assessed [36–39]. Early start of ERT has been suggested because irreversible organ
damage, cardiac fibrosis or severe renal dysfunction, would render the therapy ineffective [34,36,40].
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry
disease have recently been provided by the European Fabry Working Group consensus document [28].
The effect of ERT on patients with mild mutations, which retain some residual AGAL activity, has not
been considered separately [41]. This is unfortunate because ERT is not the only possible therapy for
Int. J. Mol. Sci. 2016, 17, 2010 3 of 16
FD. A new approach with pharmacological chaperones (PC) has been proposed and a small molecular
weight molecule is on the verge of being approved with the commercial name of Galafold™. This drug
is an iminosugar, which closely resembles the natural product of AGAL galactose, and has been known
by different names, 1-deoxygalactonojirimycin (DGJ), migalastat, AMIGAL, AT1001. DGJ inhibits
reversibly AGAL at nanomolar concentrations, but stabilizes the wild type enzyme in vitro against
thermal [42] and chemical induced denaturation [43] too. DGJ can be used in synergy with ERT
either co-administrating both drugs intravenously or one orally (DGJ) and the other intravenously
(recombinant enzyme). DGJ prolongs the half-life of AGAL in vivo, both in mouse models and in
humans and leads to an improved clearance of Gb3 [44–46].
DGJ can be used for a stand-alone oral therapy of FD for specific missense genotypes. The efficacy
of DGJ was tested in vitro, ex vivo, in cells derived from patients, and in vivo. Oral administration
of DGJ reduces Gb3 in kidney, heart and skin of Fabry transgenic mice carrying the responsive
human mutation R301Q [47]. When administered with an oral dose of 150 mg, it was well tolerated,
increased AGAL activity [48] and decreased plasma lyso-Gb3 [47] in the majority of the patients with
responsive GLA mutations. Interestingly, the best results are obtained when an intermittent regimen
is used. The results of a clinical trial phase 3 study carried out on males and females affected by
FD has been recently published. Patients received 150 mg of Galafold™ or placebo every other day.
The study began with six months of double-blind administration and proceeded with 6 + 12 months
of open-label administration. Although the authors conclude their abstract stating quite cautiously
that “the percentage of patients who had a response at 6 months did not differ significantly between
the migalastat (DGJ) group and the placebo group”, promising results are shown. A reduction of the
number of Gb3 inclusions per kidney interstitial capillary as well as a reduction of plasma lyso-Gb3
were observed [49].
More than 700 variants have been reported in HGMD for the GLA gene so far and, differently
from other lysosomal disorders such as Gaucher, there are not prevalent mutations, on the contrary
most are usually found only in a single family. The number of missense mutations, 467 described so
far, is a surprisingly high value for a medium size protein, such as AGAL. In order to appreciate this
finding it should be considered that more than 70,000 missense mutations affecting proteins associated
to human diseases have been reported, with seven variants per protein on average. The large number of
missense mutations poses several problems for making a diagnosis and initiating the most appropriate
therapy. Recently, it was proposed to use residual activity measured in vitro to classify mutations.
We wish to contribute to the evaluation of such a proposal with the first meta-analysis of the residual
activity of GLA missense mutations measured by several independent research groups employing
different protocols, either ex vivo, in cells derived from patients, or in vitro, in transiently transfected
cells. Results covering 317 of missense mutants, mostly cases reported in HGMD and associated to
FD, were collected. Data were obtained in the absence or in the presence of DGJ. For this reason,
our analysis provides an independent perspective on the amenability to pharmacological chaperones.
In addition to this we reviewed other small molecules that were reported to have a stabilizing effect on
some GLA missense mutations in vitro and might be developed to act in synergy or as an alternative
to DGJ.
2. Results
Meta-Analysis of Data Reporting Residual Activity and Responsiveness to DGJ of GLA Missense Mutations
Several independent groups have tested the effect of DGJ on AGAL mutants, administering the
drug to cells derived from patients, or most frequently, to HEK293 or COS cell transiently transfected
with expression plasmids. The enhancement of enzyme levels and that of the total enzyme activity
is monitored in the cells extracts and is regarded as a proof of the stabilization of the mutant in the
cell by DGJ. Residual activity is normalized by the total amount of protein in the cell and should not
be confused with specific activity, which is normalized by the amount of AGAL. Residual activity
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is influenced by the stability of the mutant in the cell and by its specific activity. In general, a fixed
concentration of DGJ was used, usually 20 µM, in some cases, however, IC50 was determined and the
optimal concentration was used. The results gathered from literature are reported in Supplementary
File S1 and the methods employed in each study are summarized in Table 1.
Table 1. Experimental conditions under which DGJ responsiveness has been assessed.
Reference Cell Type Concentration and Incubation Time
Ishii_2000 [50] Transfection COS1 20 µM DGJ 1 day
Spada_2006 [10] Transfection COS7 20 µM DGJ 72 h
Shin_2007 [51] T-cells and fibroblasts 20 µM DGJ 3 or 4 days
Ishii_2007 [52] Lymphoblasts and fibroblasts 20 µM DGJ 5 days
Shin_2008 [53] T-cells 20 µM DGJ 3 days
Park_2009 [54] Transfection COS7 20 µM DGJ 2 days
Benjamin_2009 [55] Lymphoblasts and fibroblasts Depending on EC50 5 days
Filoni_2010 [56] Transfection COS1 and lymphocytes 20 µM DGJ 72 h
Wu_2011 [57] Transfection HEK293 Depending on EC50 4 to 5 days
Andreotti_2011 [58] Transfection COS7 20 µM DGJ 48 h
Lukas_2013 [2] Transfection HEK293H 20 µM DGJ 60 h
Giugliani_2013 [59] Transfection HEK293 10 µM DGJ
Lukas_2016 [60] Transfection HEK293 20 µM DGJ 60 h
The last criteria for responsiveness were adopted for the clinical trial phase 3 published in 2016 [49]
and require a relative increase in AGAL activity ≥1.2-fold above baseline and an absolute increase in
AGAL ≥ 3% of wild type after incubation with 10 µM DGJ. The concentration of 10 µM is the Cmax
concentration in plasma when patients are treated with 150 mg of DGJ, as was the case in clinical
trials [47,49]. Ten micromolar, however, is not the highest concentration that can be safely reached
in plasma [59,61] and the data obtained before 2016 with 20 µM DGJ, can still be useful to choose
eligible patients.
In vitro results are robust and do not depend on the type of recipient cells used for transfection
(Figure 1).
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Figure 1. The residual activity of mutants transiently transfected and expressed in COS7 and in HEK293
is shown. In the case that multiple reports are available for a given mutant and a given recipient cell
type, the average value was plotted. Results in the absence of DGJ (A) or in the presence of DGJ (B)
are reported.
On the other hand, residual activity measured ex vivo varies among individuals and type of
cells. A few examples of the levels measured in white blood cells are provided with the average,
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standard deviation and number of individuals: E66Q 42.3 ± 12.5 (n = 9) [62]; A143T 35.9 ± 7.2 (n = 4),
R112H 7.2 ± 7.0 (n = 5), R301Q 7.3 ± 2.7 (n = 6), R356W 1.2 ± 1.9 (n = 4) (Supplementary File S1).
Figure 2 shows the average residual activity measured in lymphoblasts or in fibroblasts harboring
the same mutation. A moderate yet statistically significant correlation of the data is observed only in
the presence of DGJ.
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are reported.
Figure 3 compares the residual activity easured ex vivo in cells d rived from patients,
(mostly lymphocytes or, in a few cases, fibroblasts), with that measured, in vitro, in transfected cells
(HEK293, COS7 or COS1). For each mutant, the averages among results obtained by different authors
without (Figure 3A) or with DGJ (Figure 3B) was determined. It can be observed that the residual
activity measured in cells derived from patients tends to be lower than that measured in transfected
cells, in particular in the absence of DGJ. A few examples are provided indicating in vitro result
in HEK293H cells, ex vivo results in leucocytes with average, standard deviation and number of
individuals: L180F: 32.4%, 6.0 ± 2.0 (n = 2); N215S: 39.5%, 27.1 ± 16.3 (n = 10); and I253T: 73.0%,
22.6 ± 6.9 (n = 3).
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However, the residual activities in vitro and ex vivo correlate (Figure 3A r = 0.7, p < 0.01; Figure 3B
r = 0.7, p < 0.01). Thus, it can be concluded that tests in vitro can generally recapitulate the residual
activity ex vivo and responsiveness to DGJ.
When this manuscript had been completed, we became aware of a recent publication that reports
residual activity of AGAL mutants expressed in HEK293 cells and tested with DGJ 10 µM [63].
These data correlate with those reported in Supplementary File S1 (−DGJ r = 0.8, p < 0.000001;
+DGJ r = 0.7, p < 0.000001).
Test in vitro have a limitation because they cannot account for the effect of exonic mutation on
splicing. In fact, mutants are encoded by plasmids that do not contain introns. It is interesting to
analyze the case of the mutations affecting a site of splicing and corresponding to G183 represented by
red symbols in Figure 3. Substitution of GLY by SER results in a mutant that does not retain activity in
cells derived from patients and does not recover activity with DGJ. The same mutant recovers activity
with DGJ in vitro. We can hypothesize that the drug has a stabilizing effect on the protein, but cannot
correct the effect on splicing. On the other hand, G183A and G183D are responsive to the drug both
in vitro and ex vivo suggesting that these mutations mainly affect the protein, but not the splicing.
K213M might be another example where splicing could play a role to explain the in vitro and ex vivo
differences. Mutations not occurring at splicing sites can have effect on the maturation of RNA too.
We suspect that this might be the case for G128E, green symbol in Figure 3, because very low residual
activity was measured by several authors in cells derived from patients, either in the presence or in
the absence of DGJ, whereas the mutation retains residual activity and is responsive to DGJ in vitro.
Although a putative consensus for an exonic splicing enhancer including the triplet 128 was found,
further experiments are needed to confirm the influence of the mutation on RNA processing.
We report the score obtained by a position specific substitution matrix (PSSM) that measures
whether the mutation was tolerated during the evolution of homologous proteins in Supplementary
File S2. Mutations affecting the active site, as expected, have no residual activity and do not respond to
DGJ, mutations occurring at non-conserved sites tend to be responsive.
Predictions were obtained with Web based Polyphen2 using HumDiv or HumVar as the training
set and are reported in Supplementary File S2. Both sets use disease mutations in UniprotKB as positive
controls, but differ for the negative control set. HumDiv uses differences between human proteins and
their closely related mammalian homologs, whereas HumVar uses common human SNPs (MAF > 1%)
without annotated involvement in disease. HumVar-trained model is suitable to distinguish mild
mutations, the HumDiv-trained model, considers also mild mutations as deleterious one. Although,
on average, the residual activity of mutations that are predicted as probably damaging with both
training sets is very different from the residual activity of mutations predicted as benign, exceptions
can be observed in particular with HumVar-trained model (Table 2).
Other in silico approaches based on the structural features of AGAL, some from our group [64],
have been attempted [65,66], to predict the severity of FD genotypes. We believe that data obtained
in vitro should always be preferred whenever available.
In Supplementary File S2, all missense variants of GLA described in ExAC [67] are reported.
ExAC summarizes exome sequencing data from a wide variety of large-scale sequencing projects.
Variants reported in this database, in particular those observed with higher frequency, are likely to
be non-pathogenic. The mean residual activity measured in vitro for a subset of ExAC variants, i.e.,
those observed in more than one male is reported in Table 2. The number of hemizygous individuals
reported in ExAC, the PSSM score, Polyphen2 prediction and the reference found in HGMD are
reported in the same table.
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Table 2. Putative non-pathological AGAL mutants: features and residual activity in vitro.
Mutation No. Hemiz −DGJ +DGJ PSSM Humdiv Humvar Reference
L3P 4 117.7 129.4 −3 Probably damaging Probably damaging [60]
E66Q 3 47.6 53.66 −2 Probably damaging Probably damaging [68]
R118C 8 24.5 27.8 −2 Probably damaging Possibly damaging [10]
N139S 7 147.8 176.4 −1 Benign Benign [69]
S126G 18 51.3 67.4 −2 Benign Benign [70]
A143T 19 39.7 63.7 −1 Probably damaging Possibly damaging [71]
I289V 3 79.9 95 0 Probably damaging Possibly damaging
D313Y 129 75.5 100.3 −1 Probably damaging Possibly damaging [71]
R363H 3 28 65.7 −1 Benign Benign [72]
A368T 3 103.7 93.3 0 Benign Benign [2]
T385A 36 45 48.9 −2 Possibly damaging Benign [2]
W399S 5 53 51.5 −4 Possibly damaging Benign [60]
R118C is the variant with the lowest residual activity, only 24.5% of wild type when tested in
transiently transfected cells. It is relatively frequent in the European population, but it is predicted as
deleterious both by Polyphen_Humvar and Polyphen_Humdiv. Oliveira and colleagues reviewed the
clinical, biochemical and histopathology data obtained from 22 individual carriers and reached the
conclusion that it “does not segregate with FD manifestations at least in a highly-penetrant Mendelian
fashion”, but might be a risk factor for stroke [73]. In accordance with this, low levels of lyso-Gb3,
a biomarker of FD, were measured in the carriers [2]. R118C is considered amenable to DGJ according to
galafold amenability table [63]. R118C was tested with DGJ and with Rosiglitazone by Lukas et al. [74].
Although in terms of activity fold increase, the effect of mono-therapy with either drug was small,
the combinatorial effect was significantly higher.
A143T has an average residual activity of approximately 39.7% of wild type. Brand and
coworkers [75] analyzed 15 females and 10 males carrying this mutation. They observed that
female and male A143T carriers showed less organ involvement in comparison to FD patients with
other missense mutations and those suffering from stroke/TIA showed no further FD-typical organ
manifestations. They came to the conclusion that “A143T seems not to be causal for FD, but rather
a genetic variant of unknown significance or a genetic modifier”. A143T is considered amenable for
the therapy with DGJ according to the galafold amenability table.
E66Q has specific activity, Vmax, and affinity for the artificial substrate 4-methylumbelliferyl-
α-galactopyranoside, Km, similar to those of wild type, but residual activity in transfected cells is
approximately one half of the wild type, possibly because the stability at neutral pH is reduced [52].
The mutation is relatively frequent in East Asian population. Sakuraba and coworkers measured the
activity in 20 Japanese or Korean male carriers with renal and cardiovascular disorders and found 13%
to 26% of the normal mean values for plasma and 24% to 65% of the normal mean values for white blood
cells, but the lyso-Gb3 levels were as low as those of healthy controls and no inclusion bodies were
found [62]. Hu and co-workers found that the mutation segregated with renal disease in a very large
Chinese family, but they did not measure the accumulation of the substrate or of lyso-Gb3 in the same
patients [76]. The involvement in cardiovascular disease has also been suspected, but no accumulation
of Gb3 was found in the heart of a patient carrying E66Q [77]. The association between E66Q and the
risk cerebral small-vessel occlusion is debated [78,79]. In conclusion, pathogenicity of E66Q is still
vexata quaestio. E66Q is considered non amenable for DGJ according to galafold amenability table,
but an increase in activity upon drug administration was measured by other authors [52,55,57,80].
D313Y was first associated to classic phenotype [71]. Subsequent data clinically and biochemically
indicated that D313Y should be considered a variant [81]. Cardiac, nephrological, neurological,
laboratory and quality of life data were collected from carriers of D313Y with a 4-year follow up and
the results indicated that the mutation is non pathological. Very low levels of lyso-Gb3 were found [2].
The opinion that D313Y is a non-pathological variant is supported by the fact that its frequency of
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0.4% in the non-Finnish European population is much higher than the prevalence of FD in the same
population. D313Y is considered amenable for DGJ.
For other mutations such as S126G and N139S, the clinical picture did not include specific signs
of FD [69,70]. Both mutations are considered amenable for DGJ.
This survey would suggest that a residual activity higher than 25% can indicate a non-pathological
variant. Nonetheless, when considering administration of a therapy, if any, clinicians should be aware
of the fact that the severity of the disease depends not only on the damage caused to the protein itself
by the mutation, but also by other factors, which regrettably have not yet been clarified. It should be
considered that the phenotype can differ even among the members of the same family [82] and that
the residual activity in plasma or in white blood cells can vary largely in people carrying the same
mutation [62].
N215S is a mutation affecting glycosylation of the AGAL enzyme [83]. It presents with
a proportionally high residual activity >25% of normal. It is considered a distinct sub-type of FD
due to its elevated prevalence compared to non-N215S FD cases and late-onset occurrence [60,84].
Interestingly, this variant has never been scrutinized to cause a pathogenic phenotype. By contrast,
it is believed to cause a specific cardiac phenotype. Other cardiac-prone mutations might exist,
e.g., the so-called IVS4 + 919G > A splice mutation highly prevalent in the Taiwanese population.
A clinical trial investigating the long term clinical course of N215S patients is currently ongoing
(clinicaltrials.gov, NCT01429597). In this case, the diagnostic and prognostic value of biomarker
lyso-Gb3 can be appreciated. While apparently all (genetically) found patients were identified it was
demonstrated that Gb3 was normal in a great fraction of patients. Meehan et al. [85] showed that
N215S was present in a patient with renal manifestation and is, thus, suggestive to cause mainly
cardiac and renal symptoms. N215S is amenable for DGJ.
3. Future Perspectives for Therapy
DGJ is a promising drug, but it might not be the ideal drug yet. DGJ inhibits AGAL at nanomolar
concentration and stabilizes it at micromolar concentrations. Therefore a continuous exposure to the
drug can promote AGAL levels, but not AGAL intracellular activity. Reduction of Gb3 concentration
was not observed in fibroblasts derived from patients carrying the mutations R301Q or L300P and
incubated with DGJ for 10 days, but was observed if the incubation of seven days with the drug was
followed by a three day wash-out [55].
The discovery of DGJ was the result of an educated guess, and not of a methodical screening [86].
In fact, DGJ is a glycomimetic with a six-atom ring and very closely resembles the galactose, which is the
natural product and inhibitor, and also the first chaperone described for AGAL [87]. A more systematic
search was started with the aim of finding other drugs that might have a better ratio between the
stabilizing and the inhibitory effect. Most of the molecules considered so far are glycomimetics as
DGJ itself. DGJ is an amine and is positively charged at neutral pH. In order to facilitate its diffusion
through membranes, alkylation was proposed [88]. Contrary to what was observed for analogous
iminosugars active on other lysosomal glycosidases, alkyl-DGJ derivatives had a lower affinity for
AGAL and apparently a lower chaperoning potential probably because one important hydrogen-bond,
the one established between the heterocyclic NH proton and D170 of AGAL, is lost.
On the contrary, aryl DGJ-derivatives (1-deoxygalactonojirimycin-arylthioureas) that form
a hydrogen bond between the aryl-N’H thiourea proton and D231 of AGAL, act as reversible inhibitors
and chaperones. When tested at 30 µM concentration on Q279E or R301Q mutants, the best candidate,
namely N’-p-methoxyphenyl-DGJ-Aryl thiourea, had a seven fold higher chaperoning activity than
DGJ at its optimal concentration [89].
Iminosugars characterized by a smaller, five-atom ring system, have been described [90,91].
2,5-dideoxy-2,5-imino-D-altritol (DIA) inhibited AGAL and stabilized it against thermal denaturation
and acted as a chaperone when tested on Fabry R301Q lymphoblasts although at a concentration
20 times higher than the optimal one for DGJ. The effect on Gb3 accumulation was not tested.
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One derivative of DIA possessing an aminomethyl group showed a chaperoning effect higher than
DGJ when administered to N215S patient lymphocyte cell line at high concentration (100 µM) [92].
DGJ binds and inhibits AGAL both at neutral pH, which is required, and at acidic pH, which is
not required [42]. It would be useful to find molecules that bind and stabilize AGAL mutants when
they are in the neutral environment of the endoplasmic reticulum, but dissociate when the protein
reaches the lysosome. This point was specifically addressed incorporating an orthoester segment into
DGJ [93].
Glycomimetics require a precise dosing, whereas non carbohydrate mimetics might offer a larger
therapeutic window and an improved therapeutic index. In order to look for chemically diverse
drugs, a library of 230,000 diverse compounds was screened but no inhibitors or activators of a-Gal
A with an IC50 below 50 µM were identified. Unfortunately the screening procedure relied only
on an enzymatic assay carried out at pH 5.9, but not at neutral pH or on assays based on AGAL
stabilization [94].
So far reversible inhibitors of AGAL that act as PC have been described. The association between
the two effects, inhibition and stabilization, is avoidable because active sites are not the only targets for
chaperones. Allosteric ligands might act as pharmacological chaperones, and might be more effective
than reversible inhibitors, since they would perform their stabilizing action without competing with
the natural substrate. Looking for allosteric PC is difficult because they do not resemble chemically
known substrates. Large libraries of structurally diverse compounds should be tested and preliminary
screening in silico might be functional. Allosteric ligands do not bind the active site, but one of the
many pockets occurring on the surface of a protein. Therefore it is difficult to restrict the area where
binding is allowed as required by structure based virtual screening. A recent screening, carried out
on 10,000 molecules, showed that it is possible to find molecules that, at least in silico, preferentially
bind an allosteric site than the active site. The two sites are located at the opposite sides of the catalytic
domain of AGAL [95].
The PC that have been described previously are specific ligands of AGAL. They are effective on
missense mutations that cause destabilization of the enzyme and, ultimately, its early degradation.
Other small molecules that do not physically interact with AGAL, but have effect on proteostasis,
can be considered for the treatment of these cases as well. Proteostasis regulators can be used in
synergy with specific PC potentiating their action or allowing lower dosages.
The before mentioned Rosiglitazone, a Peroxisome proliferator-activated receptor gamma (PPARγ)
agonist rearranges global cellular ubiquitination by inhibiting the ubiquitin-proteasome system (UPS).
It displayed the highest beneficial effect on mutations with a significant residual activity (e.g., R118C
and T385A) and was even more effective in combination with a PC [60]. Mechanistic studies are
required to explain why other ubiquitination inhibitors such as Pyr-41 failed to increase AGAL activity.
This finding might be ascribed to intense adverse effects of cellular ubiquitination inhibition caused by
Pyr-41 and associated toxicological aspects.
Ambroxol, a mucolytic agent used in the treatment of respiratory diseases, was identified as
an enhancer of AGAL activity. The compound has formerly been demonstrated to act as a PC on
mutant Glucocerebrosidase in Gaucher disease. Even though its mechanism of action is not known it
was demonstrated to increase cellular AGAL level and activity of most (DGJ−) amenable mutations
(E59K, A73V, A143T, A156V, I232T, R301G, R301Q, R356W and R363H) indicating an impact on AGAL
proteostasis. Ambroxol was, however, not effective as a monotherapy, but only in the combination
with a PC, galactose or DGJ [60].
The synergistic effect of N′-p-methoxyphenyl-DGJ-Aryl thiourea with two proteostasis regulators,
4-phenylbutyric acid and celastrol has been assessed. The latter compound was not effective,
but 4-phenylbutyric acid at 0.1 mM concentration was able to enhance the chaperoning activity
of the aryl-thiourea (20 µM) on the fibroblasts harbouring Q279E [89].
The effects of lactacystin 2 µM (a proteasome inhibitor) and kifunensine 0.2 mM (an inhibitor of
ER α-mannosidase I) on the processing on some mutants assessing the amount of protein was tested
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by Fan and coworkers [52] They found that some mutants responded to both drugs (F113L, N215S,
and M296I), one responded only to lactacystin (E66Q), others only to kifunesine (M72V, I91T, A97V,
R112H, L166V, and Q279E), and others had low or no response to either (A20P, A156V, M296V, R356W,
G373D, G373S, E59K, and P146S). All mutants that are responsive to kifunensine or lactacystin are also
responsive to DGJ, while A156V, M269V, R356W, and E59K are responsive only to DGJ. These results
suggest that a different cocktail of drugs might be ideal for specific AGAL mutations.
4. Methods
Residual activities in Supplementary File S1 were obtained from the literature. In those cases
where the authors did not report the normalized percentage values, the activity of the mutant in the
presence of DGJ was divided by the activity of wild type AGAL multiplied by 100 (+DGJ/wild × 100).
The reference wild type activity, measured in the absence of DGJ was obtained for each mutation from
the appropriate paper. IC50 values are reported when available.
Pearson correlation coefficients and two tailed p-values were calculated as described by
Lowry [96].
PSSM values were calculated as described [97,98]. Active site residues were identified with
DrosteP [99]. Predictions were obtained with Web based Polyphen2 using HumDiv or HumVar as the
training set under default conditions [100].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/12/2010/s1.
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